Ulcerative colitis: predictors of budesonide multimatrix treatment failure

  • Greenberg S & al.
  • Inflamm Intest Dis
  • 1 Aug 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • More than half of the patients with mild to moderate ulcerative colitis (UC) respond to treatment with oral, extended-release budesonide multimatrix (MMX); patients less likely to respond include men and those aged ≤29 years at diagnosis.

Why this matters

  • Budesonide MMX offers potential safety benefits over commonly used systemic corticosteroid therapies for UC, but it may have limited efficacy among some populations.

Study design

  • Researchers studied the health records of patients with UC treated with budesonide MMX (N=96; median age, 38.0 [interquartile range, 28-53.5] years; 72% women), using univariate and multivariable analyses to identify factors associated with inadequate response.
  • Funding: Crohn’s and Colitis Foundation; NIH.

Key results

  • Most of the patients (54%) responded to budesonide MMX, but 46% were nonresponders requiring transition to prednisone.
  • Predictors of MMX nonresponse included male sex (39% vs 19% [P=.035]; aOR, 2.96 [95% CI, 1.12-7.77]) and age ≤29 years at UC diagnosis (median age, 23.5 vs 29 years [P=.034]; aOR, 3.10 [95% CI, 1.21-7.95]).

Limitations

  • Retrospective, single-centre design with a small sample size.